Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00950352 · ClinicalTrials.gov registry record · Phase 3
Citicoline Treatment of Methamphetamine Dependence
A Phase 3 study, sponsored by Perry Renshaw.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT00950352 is a Phase 3 study that has completed, run by Perry Renshaw. The registered enrollment target is 104 participants.
The verdict
NCT00950352, a Phase 3 study, has completed, sponsored by Perry Renshaw.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if citicoline (a nutritional supplement) is effective in helping people reduce their dependence on methamphetamine. The investigators will use neuroimaging to look at the structure and chemical make up of the brain at the start of the study and after 8-9 weeks of treatment of citicoline or placebo.
Interventions
- DRUG Placebo
- DRUG Citicoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00950352
The ClinicalTrials.gov registry entry for NCT00950352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perry Renshaw, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00950352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00950352 about?
NCT00950352 is a clinical study titled "Citicoline Treatment of Methamphetamine Dependence". The purpose of the study is to determine if citicoline (a nutritional supplement) is effective in helping people reduce their dependence on methamphetamine. The investigators will use neuroimaging to look at the structure and chemical make up of the brain at the start of the study and after 8-9 week...
What is the current status of trial NCT00950352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2010-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00950352?
The interventions under investigation include: Placebo (DRUG), Citicoline (DRUG).
Who is sponsoring clinical trial NCT00950352?
This trial is sponsored by Perry Renshaw, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.